company background image
PAR logo

Paradigm Biopharmaceuticals ASX:PAR Stock Report

Last Price

AU$0.23

Market Cap

AU$84.1m

7D

-6.1%

1Y

-75.4%

Updated

13 Jun, 2024

Data

Company Financials +

Paradigm Biopharmaceuticals Limited

ASX:PAR Stock Report

Market Cap: AU$84.1m

PAR Stock Overview

Engages in the research and development of therapeutic products for human use in Australia.

PAR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Paradigm Biopharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Paradigm Biopharmaceuticals
Historical stock prices
Current Share PriceAU$0.23
52 Week HighAU$1.09
52 Week LowAU$0.23
Beta0.99
1 Month Change-17.86%
3 Month Change-42.50%
1 Year Change-75.40%
3 Year Change-88.44%
5 Year Change-83.69%
Change since IPO-37.84%

Recent News & Updates

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22
Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17
Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22
Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24
We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28
Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29
When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Shareholder Returns

PARAU BiotechsAU Market
7D-6.1%-1.5%-0.7%
1Y-75.4%-0.5%8.2%

Return vs Industry: PAR underperformed the Australian Biotechs industry which returned -0.5% over the past year.

Return vs Market: PAR underperformed the Australian Market which returned 8.2% over the past year.

Price Volatility

Is PAR's price volatile compared to industry and market?
PAR volatility
PAR Average Weekly Movement8.7%
Biotechs Industry Average Movement11.4%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market3.2%

Stable Share Price: PAR's share price has been volatile over the past 3 months.

Volatility Over Time: PAR's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aPaul Renniewww.paradigmbiopharma.com

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Paradigm Biopharmaceuticals Limited Fundamentals Summary

How do Paradigm Biopharmaceuticals's earnings and revenue compare to its market cap?
PAR fundamental statistics
Market capAU$84.09m
Earnings (TTM)-AU$69.00m
Revenue (TTM)AU$42.05k

1,916x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PAR income statement (TTM)
RevenueAU$42.05k
Cost of RevenueAU$11.47k
Gross ProfitAU$30.58k
Other ExpensesAU$69.03m
Earnings-AU$69.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.20
Gross Margin72.73%
Net Profit Margin-164,092.68%
Debt/Equity Ratio0%

How did PAR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.